Skip to main content
About CLAs



MRI and/or CT imaging of affected areas is recommended as the first screening imaging for suspected CLAs.

Skeletal survey or radiographs recommended as second imaging technique and for long-term monitoring.

Dynamic contrast-enhanced magnetic resonance lymphangiogram (DCMRL) may be needed to image the central lymphatics.

Providers may recommend one or more of the following tests to aid in a diagnosis and monitoring:

  • Biopsy
  • Bone scan
  • Bronchoscopy
  • CT scan
  • MRI
  • Lymphangiogram
  • Skeletal survey
  • Ultrasound
  • X-ray

Laboratory evaluation often includes

  • Complete blood count (CBC), complete metabolic panel (CMP), and coagulation studies
  • Immune testing may be required

Genetic testing

  • Genetic testing of involved tissue is needed to help identify potential causative somatic gene variants and guide targeted therapy
  • Important to keep in mind that
    • Affected tissue must be tested due to the nature of somatic variants (not present in all cells)
    • While affected tissue must be the sample used for genetic testing, the frequency of mutations in affected tissue is low which can make it difficult to detect mutations